Merit Medical (MMSI) is a Top-Ranked Momentum Stock: Should You Buy?

Core Insights - Zacks Premium offers tools to enhance investor confidence and market engagement through daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform the market in the next 30 days [2][3] - Stocks are rated A, B, C, D, or F, with A being the highest score indicating a better chance of outperforming [3] Value Score - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Growth Score - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - The Momentum Score identifies stocks with upward or downward trends based on price changes and earnings estimates, aiding in timing purchases of high-momentum stocks [5] VGM Score - The VGM Score combines Value, Growth, and Momentum Scores, serving as a comprehensive indicator alongside the Zacks Rank [6] Zacks Rank - The Zacks Rank utilizes earnings estimate revisions to help investors build successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.75% since 1988, significantly outperforming the S&P 500 [7][8] - There are over 800 top-rated stocks available, making selection challenging for investors [8] Stock Selection Strategy - Investors should prioritize stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize potential success [9][10] Company Spotlight: Merit Medical Systems, Inc. (MMSI) - Merit Medical, based in South Jordan, UT, specializes in peripheral and cardiac intervention products [11] - MMSI holds a Zacks Rank of 3 (Hold) with a VGM Score of A and a Momentum Style Score of B, having increased by 2.6% over the past four weeks [11] - Six analysts have raised their earnings estimates for fiscal 2025, with the Zacks Consensus Estimate increasing by $0.25 to $3.60 per share, and an average earnings surprise of +12.9% [12]